Medicine Overview

Adult Dose
Clinical InformationAdministration Information
Indication: Acutely decompensated heart failure
Age: Adult
Dose: Intravenous – Loading dose: 6-12 mcg/kg
Frequency: infusion over 10 minutes
Note: Dose and duration of treatment are individualised according to the patient’s clinical condition and response. Hepatic Impairment Severe: Contraindicated.
Indication: Acutely decompensated heart failure
Age: Adult
Dose: Intravenous – Maintenance: 0.1 mcg/kg/min
Frequency: continuous infusion
Note: May decrease to 0.05 mcg/kg/min if significant hypotension or tachycardia occur or may increase to 0.2 mcg/kg/min if the initial dose is tolerated and an increased haemodynamic effect is required.

Child Dose
Clinical InformationAdministration Information
Age: Child
Dose: No approved pediatric dosage available
Note: No approved pediatric dosage available

Renal Dose
Clinical InformationAdministration Information
Condition: Renal Impairment
Dose: Dosage - Not provided
Note: Contraindicated
Administration

Levosimendan is administered via continuous intravenous infusion, preferably through a central venous catheter. The concentrate must be diluted in 5% glucose prior to use to a final concentration of 0.05 mg/mL. An optional loading dose of 6 to 12 micrograms/kg may be infused over 10 minutes, followed by a maintenance infusion of 0.1 micrograms/kg/min, adjustable between 0.05 and 0.2 micrograms/kg/min based on hemodynamic response and tolerability for up to 24 hours. Monitor blood pressure, heart rate, and electrolytes during and for several days after infusion. It is contraindicated in severe renal or hepatic impairment and severe hypotension. Use with caution in pediatric populations and patients with mild to moderate renal or hepatic impairment.

Side Effect

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.